ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,346.60
-0.12%
Dow Jones
38,853.50
-0.08%
US Dollar vs MXN
18.3317
2.49%
Brent Oil
79.585
-0.37%
Bitcoin
68,959.87
-2.54%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Forte Biosciences Inc (FBRX)

  7. Forte Biosciences Inc (FBRX) Noticias

FBRX Forte Biosciences Inc

0.60
0.0064 (1.08%)
Última actualización: 12:57:33
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Forte Biosciences Inc FBRX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.0064 1.08% 0.60 12:57:33
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.58 0.58 0.62 0.5936
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
13/5/202415:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/5/202415:06EDGAR2Form 8-K - Current report
16/2/202415:16EDGAR2Form 8-K/A - Current report: [Amend]
14/2/202415:54EDGAR2Form SC 13G - Statement of acquisition of beneficial..
05/1/202416:27EDGAR2Form SC 13D/A - General statement of acquisition of..
03/1/202415:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202415:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202309:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202317:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/12/202318:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/12/202318:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/12/202315:05EDGAR2Form 8-K - Current report
22/11/202316:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202315:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/10/202315:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/10/202315:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/9/202315:16EDGAR2Form 8-K/A - Current report: [Amend]
20/9/202316:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/9/202316:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/9/202316:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/9/202316:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/9/202316:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/9/202315:15EDGAR2Form 8-K - Current report
20/9/202315:05EDGAR2Form 8-K - Current report
14/9/202315:00EDGAR2Form DFAN14A - Additional definitive proxy soliciting..
14/9/202309:50BWISS and Glass Lewis Recommend Forte Biosciences Stockholders..
10/9/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
08/9/202315:36EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
06/9/202315:31EDGAR2Form DFAN14A - Additional definitive proxy soliciting..
06/9/202314:15BWConcerned Stockholders of Forte Biosciences and Its..
01/9/202316:25EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
31/8/202316:29EDGAR2Form DFAN14A - Additional definitive proxy soliciting..
31/8/202313:31EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
29/8/202316:57EDGAR2Form S-3 - Registration statement under Securities Act of..
25/8/202316:17EDGAR2Form DFAN14A - Additional definitive proxy soliciting..
25/8/202309:10EDGAR2Form DEFC14A - Definitive proxy statement, contested..
25/8/202307:00BWConcerned Stockholders of Forte Biosciences File Definitive..
24/8/202305:15EDGAR2Form DEFC14A - Definitive proxy statement, contested..
23/8/202315:47EDGAR2Form SC 13D - General statement of acquisition of beneficial..
17/8/202308:30EDGAR2Form PRRN14A - Non-management revised preliminary proxy..
15/8/202316:15EDGAR2Form SC 13D/A - General statement of acquisition of..
14/8/202316:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202308:20EDGAR2Form SC 13D/A - General statement of acquisition of..
04/8/202315:21EDGAR2Form 8-K - Current report
03/8/202315:31EDGAR2Form SC 13D/A - General statement of acquisition of..
02/8/202317:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/8/202317:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/8/202316:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/8/202316:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/8/202316:28EDGAR2Form PREC14A - Preliminary proxy statements, contested..

Su Consulta Reciente

NASDAQ
FBRX
Forte Biosciences
NYSE
XNR
Xanser
BIT
UC1MWJ
Unicredit Bank
USOTC
SBNYL
Signature Bank (CE)
BIT
LAFRI
ETF
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados